To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Performance of PCR/electrospray ionization-mass spectrometry on whole blood for detection of bloodstream microorganisms in patients with suspected sepsis
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Emergency Medicine, Kern Medical Center, Bakersfield, California, USA.
Show others and affiliations
2020 (English)In: Journal of Clinical Microbiology, ISSN 0095-1137, E-ISSN 1098-660X, Vol. 58, no 9, p. e01860-19Article in journal (Refereed) Published
Abstract [en]

Blood culture (BC) often fails to detect bloodstream microorganisms in sepsis. However, molecular diagnostics hold great potential. The molecular method PCR/electrospray ionization-mass spectrometry (PCR/ESI-MS) can detect DNA from hundreds of different microorganisms in whole blood. The aim of the present study was to evaluate the performance of this method in a multicenter study including 16 teaching hospitals in the USA (n=13) and Europe (n=3). First, on 2,754 contrived whole blood samples, with or without spiked microorganisms, PCR/ESI-MS produced 99.1% true positive and 97.2% true negative results. Secondly, among 1,460 patients with suspected sepsis (sepsis-2 definition), BC and PCR/ESI-MS on whole blood were positive in 14.6% and 25.6% of cases, respectively, with the following result combinations: BC+/PCR/ESI-MS-, 4.3%; BC+/PCR/ESI-MS+, 10.3%; BC-/PCR/ESI-MS+, 15.3%; and BC-/PCR/ESI-MS-, 70.1%. Compared with BC, PCR/ESI-MS showed the following sensitivities (coagulase-negative staphylococci not included): Gram-positive bacteria, 58%; Gram-negative bacteria, 78%; and Candida species, 83%. The specificities were > 94% for all individual species. Patients treated with prior antimicrobial medications (n=603) had significantly increased PCR/ESI-MS positivity rates compared with patients without prior antimicrobial treatment, 31% vs 22% (p<0.0001), with pronounced differences for Gram-negative bacteria and Candida species. In conclusion, PCR/ESI-MS showed excellent performance on contrived samples. On clinical samples, it showed high specificities, moderately high sensitivities for Gram-negative bacteria and Candida species, and elevated positivity rates during antimicrobial treatment. These promising results encourage further development of molecular diagnostics on whole blood for detection of bloodstream microorganisms in sepsis.

Place, publisher, year, edition, pages
American Society for Microbiology , 2020. Vol. 58, no 9, p. e01860-19
Keywords [en]
Sepsis, bacteremia, direct detection, PCR/ESI-MS
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-84767DOI: 10.1128/JCM.01860-19ISI: 000575116900045PubMedID: 32641399Scopus ID: 2-s2.0-85089922341OAI: oai:DiVA.org:oru-84767DiVA, id: diva2:1463833
Note

Funding Agencies:

Ibis Biosciences, a division of Abbott  

Abbott Laboratories

Cepheid  

ContraFect  

Nabriva Therapeutics AG  

Lajolla Pharmaceuticals  

Alere Corporation  

Spectral Diagnostics  

Ferring Pharmaceuticals  

Inflammix  

VICTASm  

Sanofi Pasteur Inc.  

Curetis GmbH  

Pfizer

Merck & Company

Cidara Therapeutics Inc.  

Shire  

Aridis Pharmaceuticals Inc.  

Epigenomics Inc.  

Roche Holding Genentech

Finch Therapeutics  

Seres Therapeutics Inc.  

Diasorin Molecular  

Janssen Research and Development  

NeuMoDx Molecular  

Iterum Therapeutics International 

Available from: 2020-09-03 Created: 2020-09-03 Last updated: 2025-04-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Sundqvist, Martin

Search in DiVA

By author/editor
Sundqvist, Martin
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Journal of Clinical Microbiology
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 72 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf